PFE - Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Speaking back in May on his company's Q1 2021 earnings call, Pfizer (NYSE: PFE) CEO Albert Bourla stated, "You should expect to see a lot of ... business development deals that will allow us to bring in-house a lot of potential medicines that could become [approved treatments] ... in the second part of the decade." With pre-tax profit on its COVID-19 vaccine in the high 20% range and Bourla's company guiding for $78 billion to $80 billion in revenue for 2021 (with more than $33 billion of that coming from the vaccine), there's certainly money to be spent on acquisitions. Let's look at three potential candidates that could help Pfizer to further secure its future.
If Pfizer wants to fill its pipeline with precision-medicine oncology drugs for the next decade, perhaps it will consider Blueprint Medicines (NASDAQ: BPMC) . This $5 billion biotech is the first and only company to have two internally discovered and developed medicines that received U.S. Food and Drug Administration (FDA) approval within a decade of its founding.
Image source: Getty Images.
For further details see:
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar